In the present study, we hypothesized that MUC4-related resistance to trastuzumab can be overcome through the use of a mucolytic drug, by improving the accessibility of the drug to HER2 and hence achieve a better anti-tumor effect. The gene discussed is MUC4; the disease is neoplasm.